Latest Insider Transactions at Recursion Pharmaceuticals, Inc. (RXRX)
This section provides a real-time view of insider transactions for Recursion Pharmaceuticals, Inc. (RXRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RECURSION PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RECURSION PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2022
|
Michael Secora Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,065
-0.18%
|
$12,780
$12.96 P/Share
|
|
Aug 15
2022
|
Tina Marriott Larson President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,453
-0.7%
|
$17,436
$12.96 P/Share
|
|
Aug 15
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,751
-1.06%
|
$69,012
$12.96 P/Share
|
|
Aug 04
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,500
-100.0%
|
$22,500
$9.45 P/Share
|
|
Aug 04
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
2,500
+50.0%
|
-
|
|
Aug 04
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
36,825
-3.29%
|
$331,425
$9.49 P/Share
|
|
Aug 04
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
18,500
+3.2%
|
-
|
|
Aug 04
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+5.28%
|
$62,500
$2.48 P/Share
|
|
Jul 19
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
3,000
-0.55%
|
-
|
|
Jul 08
2022
|
Zavain Dar Director |
BUY
Other acquisition or disposition
|
Direct |
2,420
+10.53%
|
-
|
|
Jul 07
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,500
-100.0%
|
$22,500
$9.07 P/Share
|
|
Jul 07
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
2,500
+50.0%
|
-
|
|
Jul 07
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
37,114
-3.39%
|
$334,026
$9.06 P/Share
|
|
Jul 07
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
18,500
+3.27%
|
-
|
|
Jul 07
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+5.4%
|
$62,500
$2.48 P/Share
|
|
Jul 01
2022
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,224
+6.6%
|
-
|
|
Jul 01
2022
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,186
+0.02%
|
-
|
|
Jul 01
2022
|
Zachary Bogue Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,260
+23.9%
|
-
|
|
Jul 01
2022
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,409
+0.23%
|
-
|
|
Jul 01
2022
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,631
+1.03%
|
-
|
|
Jun 21
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
3,000
-0.55%
|
-
|
|
Jun 14
2022
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,145
+38.28%
|
-
|
|
Jun 14
2022
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,145
+10.51%
|
-
|
|
Jun 14
2022
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,145
+50.0%
|
-
|
|
Jun 14
2022
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,145
+41.1%
|
-
|
|
Jun 14
2022
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,145
+2.85%
|
-
|
|
Jun 14
2022
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,145
+0.24%
|
-
|
|
Jun 02
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,500
-100.0%
|
$15,000
$6.34 P/Share
|
|
Jun 02
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
2,500
+50.0%
|
-
|
|
Jun 02
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
39,690
-3.7%
|
$238,140
$6.11 P/Share
|
|
Jun 02
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
18,500
+3.34%
|
-
|
|
Jun 02
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+5.49%
|
$62,500
$2.48 P/Share
|
|
May 19
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
12,000
-2.15%
|
-
|
|
May 16
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,764
-1.13%
|
$28,820
$5.67 P/Share
|
|
May 16
2022
|
Tina Marriott Larson President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,458
-0.7%
|
$7,290
$5.67 P/Share
|
|
May 16
2022
|
Michael Secora Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,069
-0.18%
|
$5,345
$5.67 P/Share
|
|
May 16
2022
|
Ramona Doyle Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
832
-0.68%
|
$4,160
$5.67 P/Share
|
|
May 16
2022
|
Shafique Virani Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
870
-0.83%
|
$4,350
$5.67 P/Share
|
|
May 12
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
12,000
-2.1%
|
-
|
|
May 05
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,500
-100.0%
|
$15,000
$6.44 P/Share
|
|
May 05
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
2,500
+50.0%
|
-
|
|
May 05
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,500
-3.49%
|
$111,000
$6.44 P/Share
|
|
May 05
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
18,500
+3.37%
|
-
|
|
May 04
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,500
-100.0%
|
$15,000
$6.47 P/Share
|
|
May 04
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
2,500
+50.0%
|
-
|
|
May 04
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
31,830
-3.01%
|
$190,980
$6.49 P/Share
|
|
May 04
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
18,500
+3.37%
|
-
|
|
May 04
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+5.61%
|
$62,500
$2.48 P/Share
|
|
Apr 29
2022
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,500
-100.0%
|
$15,000
$6.31 P/Share
|
|
Apr 29
2022
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
2,500
+50.0%
|
-
|